Charles River Laboratories, the parent company of SPAFAS, a supplier of specific pathogen free eggs and diagnostic reagents, has divested operations in Japan and Sweden.  On October 12th the company completed sale of their RMS operations in Japan to the Jackson Laboratory for $63 million in cash.  RMS generated revenue of $46 million in 2020 and distributed “research models” (research animals) to laboratories in Japan.

On the same day, Charles River completed sale of its gene therapy subsidiary CDMO in Sweden to a private investor group for $52 million in cash.  This facility was acquired as part of the purchase of Cognate BioServices during the first quarter of 2021.  The company produces DNA for gene therapy and generated $10 million in revenue in 2020.

Charles River Laboratories intends to provide research animals, services and DNA to global clients from existing facilities in the U.S. and the EU.